Table 2.
Primary and secondary outcome measures
| Point-of-care testing* | Control* | Between-group difference (95% CI)† | p value | ||
|---|---|---|---|---|---|
| Time to results, h | 1·7 (1·6 to 1·9) | 21·3 (16·0 to 27·9) | −19·6 (−19·0 to −20·3) | <0·0001 | |
| COVID-19 positive | 197/499 (39%) | 155/555 (28%) | 11·5% (5·8 to 17·2) | 0·0001 | |
| Admitted for >24 h | 428/499 (86%) | 421/555 (76%) | 10·0% (5·0 to 14·7) | <0·0001 | |
| Transferred from assessment area to correct definitive clinical area on the basis of test result‡ | 313/428 (73%) | 242/421 (57%) | 15·7% (9·1 to 22·0) | <0·0001 | |
| Time from admission to arrival in a definitive clinical area‡, h | 8·0 (6·0 to 15·0) | 28·8 (23·5 to 38·9) | −20·8 (−18·4 to −21·2) | <0·0001 | |
| Bed moves between admission and arrival in definitive clinical area‡ | .. | .. | .. | <0·0001 | |
| 0 | 43/313 (14%) | 0/236 | .. | .. | |
| 1 | 244/313 (78%) | 163/236 (67%) | .. | .. | |
| 2 | 26/313 (8%) | 56/236 (23%) | .. | .. | |
| 3 | 0/313 | 12/236 (5%) | .. | .. | |
| 4 | 0/313 | 4/236 (2%) | .. | .. | |
| 5 | 0/313 | 1/236 (<1%) | .. | .. | |
| Mean (SD) | 0·9 (0·5) | 1·4 (0·7) | −0·5 (−0·4 to– 0·6) | <0·0001 | |
| COVID-19-positive patients enrolled into other COVID-19 trials | 124/197 (63%) | 104/155 (67%) | −4·2% (−14·0 to 5·9) | 0·42 | |
| Time from admission to enrolment into other COVID-19 trials, days | 1·0 (1·0 to 3·0) | 3·0 (2·0 to 4·5) | −2·0 (−1·0 to −2·0) | <0·0001 | |
| Antibiotics used | 418/496 (84%) | 387/555 (70%) | 14·6% (9·5 to 19·5) | <0·0001 | |
| Length of stay, days | 5·1 (2·0 to 9·2) | 4·2 (1·2 to 9·6) | 0·9 (0 to 1·0) | 0·017 | |
| Intensive care unit admission | 64/499 (13%) | 42/555 (8%) | 5·2% (0·2 to 8·9) | 0·0039 | |
| In-hospital mortality | 67/494 (14%) | 69/555 (12%) | 1·1% (−2·9 to 5·2) | 0·58 | |
| 30-day mortality | 80/440 (18%) | 86/555 (15%) | 2·6% (−2·0 to 7·3) | 0·26 | |
*
Data are n/N (%) or median (IQR), unless otherwise specified.
†
Point-of-care testing group minus control group.
‡
Assessed in patients admitted for >24 h; definitive clinical area refers to a designated COVID-19-positive or COVID-19-negative ward.